The final erythromycin PBPK model applies metabolism by CYP3A4, hepatic plasma clearance, glomerular filtration and mechanism-based inhibition of CYP3A4. Overall, the model adequately describes the oral pharmacokinetics of erythromycin in healthy adults receiving different single or multiple doses of several oral dosage forms.

